Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
recent articles
Lunit and Summit Therapeutics: Research Will Use Lunit’s AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology Seoul, South Korea and Miami, Florida,...
AI models in GI/liver pathology using the Aiforia Platform Quantitative and predictive AI models in gastrointestinal and liver pathology: the Mayo Clinic experience 4 November 2026 - 12:00 PM (noon) EST REGISTER NOW Over the...
SimBioSys: Novel software transforms routinely collected MRI, pathology and clinical data into personalized five- and ten-year recurrence risk insight for women with early-stage breast cancer CHICAGO, IL – October 15, 2026 – SimBioSys®,...
Indica Labs: Learn About AI Model Interoperability with HALO AI Open AI Workflows in Digital Pathology: Model Interoperability with HALO® Date: 4 November 2026 Time: 8:00 – 9:00 PST | 11:00 – 12:00 EST | 16:00 – 17:00...
[SINGAPORE, October 19th, 2026] – /PR Newswire/ HistoIndex, a pioneer in AI-driven digital pathology for fibrotic diseases, and the Agency for Science, Technology and Research (A*STAR), Singapore’s lead public sector R&D agency, have...
Tempus: Study presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc....
